Seagen Inc
NASDAQ:SGEN
| Market Cap (Intraday) | 37.22B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $195.28 |
| 50-Day MA | $199.44 |
| 200-Day MA | $158.08 |
Seagen Inc Stock, NASDAQ:SGEN
21823 30th Drive South East, Building 3, Bothell, Washington 98021
United States of America
Phone: +1.425.527.4000
Number of Employees: 3256
Description
Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.